|Articles|March 3, 2017
Frost & Sullivan Reveal Asia as Ideal Trial Destination
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials.
Advertisement
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials. The report states that this result is due to vast treatment-naive patient pools, clinical infrastructure and low operational costs.
Read the full report
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma
2
Applying AI to Automate Workflows Without Disrupting Sites
3
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
4
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
5